China continues to pin patented drugs to the generics floor
This article was originally published in Scrip
Executive Summary
As part of China's continuing efforts to lower drug prices, the National Development and Reform Commission (NDRC) has announced another round of price cuts, this time by an average of 17% for a range of oncology, immune and blood-related products.